Home › Categories › Corporate Reports› 固形がんに対� �るCAR-T細胞療� �開発のノイル� ��ミューン・バイオテック、� �リーズCで総額約23.8億円の資� ��調達を実施

固形がんに対� �るCAR-T細胞療� �開発のノイル� ��ミューン・バイオテック、� �リーズCで総額約23.8億円の資� ��調達を実施.pdf

20210322_Implementation_of_Series_C_Round_Fundraising.pdf

Preview of 固形がんに対� �るCAR-T細胞療� �開発のノイル� ��ミューン・バイオテック、� �リーズCで総額約23.8億円の資� ��調達を実施

🔗 Source: noile-immune.com

📊 Size: 236 KB

👤 Author: Noile-Immune

⬇️ Downloads: 143

Summary

Noile-Immune Biotech Inc. has conducted a Series C funding round, securing approximately ¥2.38 billion from new investors, including Daiichi Sankyo, Binex Holdings, and others, as well as existing shareholders. The funds will be used to accelerate the clinical development of its lead pipeline, NIB-101, a PRIME CAR-T cell therapy targeting GM2, with the goal of starting clinical trials within the year.

Download File

Description

Noile-Immune Biotech Inc.

Technical Information

File Format: PDF
File Size: 236 KB
Pages: 1
Language: EN
Author: Noile-Immune
Total Downloads: 143
Last Updated: 1 month ago

Document Overview

This PDF document about 固形がんに対� �るCAR-T細胞療� �開発のノイル� ��ミューン・バイオテック、� �リーズCで総額約23.8億円の資� ��調達を実施 provides comprehensive information and guidance. Whether you're a beginner or advanced user, this resource offers valuable insights into 固形がんに対� �るCAR-T細胞療� �開発のノイル� ��ミューン・バイオテック、� �リーズCで総額約23.8億円の資� ��調達を実施.